Innate Pharma (IPHA) Logs Huge Gains

Innate Pharma has moved 17.1% so far today on a volume of 395,210, compared to its average of 71,509. In contrast, the S&P 500 index moved -0.1%. Over the last 52 weeks, the stock moved -41.7%, with a high of $5.25 and a low of $1.9. During this time, the stock lagged the S&P 500 index by -22.0%.

Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The small-cap Healthcare company has 213 full time employees and is based in Marseille, France. Innate Pharma has not offered any dividends in the last year.

Snapshot of the Company's Lack of Profitability:

2018-12-31 2019-12-31 2020-12-31 2021-12-31
Revenue (MM) $80 $69 $57 $12
Revenue Growth n/a -13.7% -17.6% -78.7%
Gross Margins 0.0% 34.53% 94.65% 0.0%
Gross Margins Growth n/a inf% 174.11% -100.0%
Operating Margins 6.44% -39.22% -32.63% -394.94%
Operating Margins Growth n/a -709.01% 16.8% -1110.36%
Free Cash Flow (MM) $-34 $-30 $-63 $-60
FCF Growth n/a 10.26% -106.87% 5.17%
Capital Expenditures (MM) $-1 $-65 $-11 $-1
Net Debt / EBITDA -12.05 21.01 -3.1 1.43

Basic Valuation Metrics Show Innate pharma Is Overvalued:

Compared to the Healthcare sector's average of 13.21, Innate Pharma has a trailing twelve month price to earnings (P/E) ratio of -4.7 and, based on its Eps guidance of 0.45, an expected P/E ratio of 7.3. Innate Pharma's price to book (P/B) ratio is 2.3 compared to its sector average of 4.07.

There is Mixed Market Sentiment About Innate Pharma:

5 analysts are following Innate Pharma and have set target prices ranging from $2.51 to $12.02 per share. On average, they have given the company a rating of buy. At today's prices, IPHA is trading -58.98% away from its average analyst target price of $8.02 per share, implying an analyst consensus of strong upside potential for the stock.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.